Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders. They focus on developing new therapies using a novel, targeted ADC based delivery platform.
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders
Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders. They focus on developing new therapies using a novel, targeted ADC based delivery platform.